Previous close | 29.40 |
Open | 29.40 |
Bid | 29.40 x N/A |
Ask | 29.80 x N/A |
Day's range | 29.40 - 29.40 |
52-week range | 19.10 - 32.00 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the co
Agios Pharmaceuticals Inc (NASDAQ:AGIO), a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of cancer and rare genetic diseases, has seen a recent insider transaction according to the latest SEC filings.